Pablo J Cagnoni has sold stock and made no open-market buys since Jul 2018

Pablo J. Cagnoni, M.D., is a biopharmaceutical executive and oncologist who serves as President, Incyte and Global Head of Research & Development (R&D) at Incyte Corp.( In this role, he oversees Incyte’s global research and development programs across hematology, oncology, inflammation and autoimmunity, including dermatology, and supports enterprise-wide strategic planning and operational execution.( A recognized leader in oncology drug development, he has played a key role in the development, approval and commercialization of more than 20 life‑changing medicines for cancer and other serious diseases.(

Before joining Incyte in 2023, Dr. Cagnoni was Chief Executive Officer of Laronde and an Executive Partner at Flagship Pioneering, following earlier leadership roles as President and CEO of Rubius Therapeutics, CEO of Tizona Therapeutics, and President of Onyx Pharmaceuticals, as well as Global Head of Clinical Development at Novartis Oncology.( Earlier in his career he served as Chief Medical Officer at Allos Therapeutics and OSI Pharmaceuticals and as an Assistant Professor of Medicine in the University of Colorado Bone Marrow Transplant Program.( Dr. Cagnoni earned his medical degree from the University of Buenos Aires School of Medicine and completed fellowships in Hematology and Oncology at Mount Sinai Medical Center in New York and in Stem Cell Transplantation at the University of Colorado Health Sciences Center.(

Written by Perplexity from public sources.